Program report · filed November 17, 2026
AI in SalesMeasured report
ODAIA Raises $15M Series C to Scale AI for Pharma Sales Teams
Toronto AI firm ODAIA raised $15M in Series C led by Monograph Capital, with PHM becoming its exclusive US agency partner to unify pharma sales and media.
By Marcus Bennett3 min read636 words
Program notes
- ODAIA raised $15 million in Series C financing led by Monograph Capital.
- PHM, a Publicis Groupe healthcare media agency, became ODAIA's exclusive US agency partner alongside a strategic investment.
- The company was founded in 2018 out of the University of Toronto and is headquartered in Toronto with a Boston office.
- ODAIA did not disclose valuation, total capital raised, or individual investor amounts.
- The platform delivers prioritized engagement plans to pharma reps through existing CRM systems.

ODAIA, a Toronto AI company, has raised $15 million in Series C financing to scale predictive commercial intelligence (software that forecasts prescribing and engagement opportunities) across pharmaceutical brands. Monograph Capital led the round, and PHM — a U.S. healthcare media agency owned by Publicis Groupe — took a strategic stake alongside returning investors BDC Capital, Flint Capital, Innospark Ventures, Graphite Ventures, Threshold Ventures and Wittington Ventures.
The deal comes bundled with a commercial platform agreement that makes PHM ODAIA's exclusive agency partner in the United States. For pharma commercial teams, that pairing matters as much as the cash: it connects ODAIA's predictive models directly with PHM's healthcare media buying, so digital campaigns and field sales activity can run off one intelligence layer instead of parallel stacks.
What changes for sellers and marketers?
ODAIA's platform ingests healthcare professional data, patient-related signals, prescription trends, field sales activity and digital engagement data, then outputs recommendations on which physicians to target, through which channels, and when. Three products carry the workload:
- Brand Strategy Studio lets brand teams define commercial strategies that the system translates into recommendations for individual healthcare professionals.
- Field Intelligence pushes prioritized engagement plans to sales reps through their existing CRM systems — no rip-and-replace.
- Marketing Intelligence coordinates personalized HCP engagement across digital advertising, marketing and partner channels.
The platform also builds in explainable AI (recommendations whose reasoning commercial and compliance teams can inspect), and it continuously measures engagement and prescription outcomes to refine future recommendations as market conditions shift.
Why the CEO says scale, not proof, is the bottleneck
"Pharma has proven that AI works in commercial. The hard part now is scaling it," said Philip Poulidis, ODAIA's chief executive officer and co-founder. He argues pharma companies have shown AI's value inside individual brands but hit extra implementation costs when extending capabilities across multiple products and therapeutic areas. ODAIA's answer is a centralized platform with shared data infrastructure and configurable decision-making tools serving several brands at once.
Charles Conn, co-founder and partner at Monograph Capital, said ODAIA has demonstrated it can convert predictive AI models into practical commercial decisions for pharmaceutical companies. Monograph previously co-led ODAIA's Series B and returned as lead investor this time — a repeat-backer signal worth noting in a market where AI vendors routinely raise on promise rather than retention.
What the company didn't disclose
ODAIA did not reveal its post-round valuation, total capital raised to date, or the individual checks written by participating investors. The $15 million figure covers the round as a whole, so treat any breakdown claims you see elsewhere as unverified. Customer counts, revenue and named pharma clients also stayed undisclosed; the company says only that its customers range from major global manufacturers to specialty biopharmaceutical businesses.
Where the money goes
ODAIA plans to spend the capital on three fronts: expanding adoption among existing pharmaceutical customers, building additional platform capabilities, and supporting broader commercial deployment across the biopharma industry. The company will keep selling directly to pharma manufacturers while staying compatible with their existing CRM systems, internal analytics models and data infrastructure — a positioning choice that keeps IT displacement costs out of the buying conversation.
Founded in 2018 out of the University of Toronto, ODAIA is headquartered in Toronto with an office in Boston. Its technology focuses on spotting prescription opportunities, predicting patient journeys, and telling commercial teams when and how to engage healthcare professionals.
The round lands as pharma manufacturers push to unify sales and marketing coordination and squeeze more decisions out of healthcare data. If Poulidis is right that scaling, not proving, is the industry's real constraint, the next signal to watch is whether ODAIA's multi-brand deployment model cuts the per-brand implementation cost curve its customers currently face.
via citybiz.co (Source)
More from Marcus Bennett
Show full bio
Staff writer covering people, launches and day-to-day practice in Sales technique and methodology, sales enablement at Quota Brief.
120 articles